On-Orbit Prospective Echocardiography on International Space Station

Douglas R. Hamilton¹, Ashot E. Sargsyan¹, David Martin¹, Kathleen M. Garcia¹, Shannon Melton¹, Alan Feiverson², Scott A. Dulchavsky³

¹Wyle Integrated Science and Engineering Group, Houston, TX
²NASA Lyndon B. Johnson Space Center
³Henry Ford Hospital Department of Surgery, Detroit, MI

This study was supported by NASA Flight Grant NNJ04HB07A and the National Space Biomedical Research Institute Grant SMS00301.
Learning Objectives

1. The audience will understand concepts behind remotely guided echocardiographic imaging from remote locations such as the ISS.

2. The audience will understand the approach of Benjamini, Krieger and Yekutieli (2001) to allow a moderate “false discovery rate” and modify the standard P-value threshold from 0.05 to a lower value for declaring “significance”

3. The audience will understand this study found no consistent effects of long-duration space flight on echocardiographic variables of the given group of subjects
Introduction

• A number of echocardiographic research projects and experiments have been flown on almost every space vehicle since 1970, but validation of standard methods and the determination of ‘Space Normal’ cardiac function has not been reported to date

• Advanced Diagnostics in Microgravity (ADUM) - remote guided echocardiographic technique provides a novel and effective approach to on-board assessment of cardiac physiology and structure using a just-in-time training algorithm and real-time remote guidance aboard the International Space Station (ISS)
Introduction – Cont.

• The validation of remotely guided echocardiographic techniques provides the procedures and protocols to perform scientific and clinical echocardiography on the ISS and the Moon

• The objectives of this study were:
  1. To confirm the ability of non-physician astronaut/cosmonaut crewmembers to perform clinically relevant remotely guided echocardiography using the Human Research Facility on board the ISS
  2. To compare the preflight, postflight and in-flight echocardiographic parameters commonly used in clinical medicine
Cardiac Monitoring Occurrences

• Selection
• Annual physicals
• Parabolic flight
• Preflight
• In Flight
• Postflight
CD-ROM based “just-in-time” On Board Proficiency Enhancement (OPE) will reduce the amount of ground-based guidance needed to acquire advanced ultrasound images.
Make it Fun!!!!!
Doppler Assessment of Myocardial Relaxation

Echocardiography parameters:

Prasad et al. Am J Cardiol 2007 Courtesy Ben Levine
Longitudinal Changes
37.5 % Range

Maximal Cross-Sectional Changes
75 % Range!

(from deGroot et al, unpublished observations)

(from Milliken et al, Am J Cardiol 1998)

Spinal cord Injury
Bed rest
Base
Training
Elite Runners

12wk
6wk
2wk
3mo
6mo
9mo
12mo

% Baseline LV Mass Index
Is cardiac function a significant concern and should it be monitored?

- Need on-orbit echo data with cardiovascular interventions to better understand the physiology and space normal clinical findings

- In the past, astronauts have not been able to “get the shot” for retrospective analysis

- Pre/Post flight data are high fidelity because experience echo technicians are collecting the data
## Experiment Design

<table>
<thead>
<tr>
<th><strong>PREFLIGHT</strong></th>
<th><strong>IN FLIGHT</strong></th>
<th><strong>POSTFLIGHT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline ultrasound scan and simulation training ~L-240 days (Incr. 8 - August 2003)</td>
<td>OPE (all increments) Operator only ≤ 7 days before scan</td>
<td>Baseline ultrasound exam ~R+10±7 days (Russia)</td>
</tr>
<tr>
<td>On-board Proficiency Enhancer (OPE) and Preflight ~L-180 and 3 days</td>
<td>Exam Scan (Cardiac, Thoracic, Abdominal, Bone, Muscle)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Analyses ** Within 7 days post scans set</td>
<td></td>
</tr>
</tbody>
</table>

** “Restricted access” voice loop required

Notes: Restricted Audio/Video Communication for real-time remote guidance sessions.
Methods

- Each crewmember operator (n=6) had 2h preflight training. Baseline data were collected 55 to 167 days preflight with HDI-5000 (ATL/Philips, Bothell, WA) ultrasound system.

- Similar equipment was used in each 60-minute in-flight session (microgravity exposure - 114 days (34 – 190)).

- Operators used an e-learning system (in this case, OPE) within 24h of these sessions. An expert in echocardiography provided assistance using ultrasound video downlink and 2-way voice.

- Testing was repeated 5 to 16 days after landing.
Data Analysis

- Separate ANOVA was used on each echocardiographic variable (n=36)
- Within each ANOVA, three tests were made:
  A. effect of mission phase (preflight, in flight, postflight)
  B. effect of echo technician (two independently analyzed the data)
  C. interaction between mission phase and technician.
- In the resulting 108 tests, some of the “significant” findings (P < 0.05) were expected to be false
- A “false discovery rate” of 15% was assumed (Benjamini, Krieger and Yekutiel approach), still retaining enough power to identify potentially important effects of mission phase, technician, or both
- A revised P-value threshold was calculated to be 0.0116
Each analyst measured the following parameters

- LA Systolic Diameter
- LV Diastolic and Systolic Diameter Base Length and Posterior Wall Thickness
- LV Mass (Simpson and m-mode)
- LV diastolic length = a+d (cm)
- LV Outflow Tract Diameter and Time Velocity Integral
- RV Area Diastole and Systole
- RA Area Diastole and Systole
- % Change in RV and RA Area
- Mitral E and A-wave Velocity
- Atrioventricular Time Velocity Integral
- Fractional Shortening
- Ejection Fraction (by area and volume)
- Interventricular Septal Diastolic and Systolic Thickness
- Isovolumic Relaxation and Contraction Time
- Endocardial and Epicardial Area
- A Wave Duration
- Heart Rate
- Diastolic and Systolic 4-Chamber Volume by 2D
- Cardiac Output
The Method of Benjamini, Krieger and Yekutieli

• When running 108 tests (36 ANOVAS, 3 tests per each), some of the “significant” findings (corresponding to $P < 0.05$) might be spurious

• To compensate for this, we used the approach of Benjamini, Krieger and Yekutieli to allow a moderate “false discovery rate” of 15%, but still retain enough power to identify potentially important mission phase, analyst, or interaction effects

• Applying this procedure for our data resulted in a revised P-value threshold of 0.0116

• If this experiment and analysis procedure were to be repeated, one would expect on average that perhaps one or two of the rejections of the NULL hypothesis were false
The Method of Benjamini, Krieger and Yekutieli – Cont.

- “Significance” is only in a statistical sense and may not represent clinically meaningful differences
- 9 tests were “significant” (i.e., a rejection of the null hypothesis) using the method of Benjamini, Krieger and Yekutieli with an FDR of 0.15
  - 6 rejections for significant technician effects (LV systolic diameter base length, LV posterior wall systolic thickness, A-wave duration, Interventricular septum diastolic and systolic thickness and LV mass)
  - 3 rejections of the null hypothesis were attributable to space flight (Atrio-ventricular velocity time integral, Mitral E wave, Heart rate)
Results

• 9 rejections of the null hypothesis (mission phase or technician or both had no effect) were found that could be considered for possible follow up

• Of these
  – 6 rejections were for significant technician effects
  – 3 were attributable to space flight
    1. Atrioventricular velocity time integral
    2. Mitral E wave
    3. Heart Rate

• None were due to the interaction between technician and space flight

• Thus, we find no significant effects of long-duration space flight on clinical echocardiographic variables for the given group of subjects
Conclusion

• Current ISS mission medical prevention strategies seem to prevent grossly obvious cardiac abnormalities.

• Remotely guided echocardiography can be used for payload science and clinical studies where temporal communication delays are less than 6 seconds (i.e., Moon and the Lagrange Point).

• If space-related changes in cardiovascular function measured by echocardiography exist, a larger cohort and more controlled conditions need to be implemented (Integrate Cardiovascular Study – Levine and Bungo – currently manifested).
Questions?

Douglas Hamilton  MD PhD MSc E Eng P. Eng
Flight Surgeon / Electrical Engineer - Wyle Life Sciences